Search company, investor...

Predict your next investment

Cota Capital company logo
Venture Capital
cotacapital.com

Investments

154

Portfolio Exits

25

Funds

8

Service Providers

1

About Cota Capital

Cota Capital is an SEC-registered multi-stage investment firm focused on private and public enterprise technology companies. Cota has invested in more than 100 private and public technology companies since inception. Cota's overall Mission is to deliver impactful outcomes through principle-guided investment in modern enterprise technologies.

Headquarters Location

455 Market Street Suite 1850

San Francisco, California, 94105,

United States

Want to inform investors similar to Cota Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Cota Capital News

CellFE secures $22 million in Series A financing to advance microfluidics-based cellular engineering platform

Sep 28, 2023

Share This Article • Financing led by M Ventures, with participation from GreatPoint Ventures, Riverine Ventures and existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital and Khosla Ventures • Novel microfluidics-based cell engineering platform for ex-vivo cell transfection enabling efficient, flexible, and consistent payload delivery, superior cell health and streamlined workflows for seamless scalability from research to manufacturing • Funding to advance the development of CellFE's technology platform and support the company's market launch and continued growth initiatives ALAMEDA, Calif., September 27, 2023-- CellFE Inc., www.cellfebiotech.com, a life sciences tools company developing a microfluidics-based cell engineering platform dedicated to transforming the development and manufacturing of advanced cell therapies, today announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures and Riverine Ventures as well as existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital, and Khosla Ventures. The continued clinical and commercial success of advanced biologic therapeutics, such as engineered cell and gene therapies, is driving substantial growth opportunities in this emerging segment of life sciences. Therapy developers are forging partnerships with technology providers, such as CellFE, to advance innovative solutions, with the aim to benefit patients seeking better therapeutic options. CellFE's innovative, non-viral, microfluidic cell engineering platform, Infinity MTx™ system, performs complex genetic cell editing through streamlined, advanced workflows. The platform ensures gentle cell treatment, rapid cell recovery, and superior yield of healthy cells, enabling unparalleled scalability and significant time and cost efficiencies in development and manufacturing. CellFE empowers therapy developers to accelerate the ongoing evolution of advanced cell therapies across a spectrum of therapeutic areas, unlocking a groundbreaking shift towards true decentralized and point-of-care manufacturing in the cell therapy sector. The launch of the Infinity MTx system at the recent ASGCT 2023 Annual Meeting elicited broad interest from top innovative cell therapy developers globally. "With our clear path to help redefine cell therapy manufacturing, we are excited to have the backing of such esteemed investors who recognize the potential of our technology and the strength of our team," said Alla Zamarayeva, CEO of CellFE. "Our vision of advancing the platform to a decentralized and point of care application will expand access to cell therapies for millions of patients." "While viral cell engineering methods have been dominating the industry to date, high costs, limited editing capabilities, regulatory hurdles, and safety concerns are driving a shift to non-viral methods. CellFE presents a unique technology platform addressing key industry pain points across viral, but also other non-viral methods," said Christian Uhrich, Principal at M Ventures. "Offering efficient, flexible, and consistent payload delivery, superior cell health, user-friendly workflows, and process scalability from development to manufacturing, we believe the company offers a compelling value proposition for the increasing number of therapy developers seeking novel solutions. We are delighted to join the company that Alla and the CellFE team have built at this exciting time and to support the company's future development, growth, and overall vision." About CellFE CellFE is an innovative microfluidics company, whose mission is to transform the development and manufacturing of lifesaving cell therapies to make them more accessible to patients. The company uses a microfluidic-based cell engineering platform with highest cell health and payload delivery, streamlined scalability and automated workflows. Platform benefits include increased cell yield and reduced expansion times that translate to drastically reduced vein-to-vein times and manufacturing costs currently associated with advanced cell therapies. CellFE is committed to enabling their partners' success through close collaborations that aim to solve the challenges associated with the development and manufacturing of next generation cell therapies. https://www.cellfebiotech.com/ About M Ventures M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck KGaA, Darmstadt, Germany's current and future businesses. http://www.m-ventures.com/

Jul 15, 2023
Jirav raises $20M

Cota Capital Investments

154 Investments

Cota Capital has made 154 investments. Their latest investment was in CellFE as part of their Series A on September 9, 2023.

CBI Logo

Cota Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2023

Series A

CellFE

$22M

No

2

9/27/2023

Series B

Farther

$31M

No

2

7/27/2023

Series B

Proprio

$43M

No

Bird B, BOLD Capital Partners, Cota Capital, DCVC, HTC, Intel, and Undisclosed Investors

4

7/11/2023

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/30/2023

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2023

9/27/2023

7/27/2023

7/11/2023

5/30/2023

Round

Series A

Series B

Series B

Series B

Unattributed

Company

CellFE

Farther

Proprio

Subscribe to see more

Subscribe to see more

Amount

$22M

$31M

$43M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Bird B, BOLD Capital Partners, Cota Capital, DCVC, HTC, Intel, and Undisclosed Investors

Sources

2

2

4

10

10

Cota Capital Portfolio Exits

25 Portfolio Exits

Cota Capital has 25 portfolio exits. Their latest portfolio exit was Miroculus on March 16, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/16/2023

Acquired

$99M

3

2/22/2023

Acquired

$99M

4

12/9/2022

Reverse Merger

$99M

8

11/28/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/28/2022

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/16/2023

2/22/2023

12/9/2022

11/28/2022

4/28/2022

Exit

Acquired

Acquired

Reverse Merger

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

4

8

10

10

Cota Capital Fund History

8 Fund Histories

Cota Capital has 8 funds, including Cota Opportunities VI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/20/2020

Cota Opportunities VI

Diversified Private Equity

Closed

$3.5M

1

12/30/2019

Cota Opportunities V

Subscribe to see more

Subscribe to see more

$99M

10

4/22/2019

Cota Opportunities IV

Subscribe to see more

Subscribe to see more

$99M

10

2/7/2019

Cota Opportunities III

Subscribe to see more

Subscribe to see more

$99M

10

5/21/2018

Cota Opportunities II

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/20/2020

12/30/2019

4/22/2019

2/7/2019

5/21/2018

Fund

Cota Opportunities VI

Cota Opportunities V

Cota Opportunities IV

Cota Opportunities III

Cota Opportunities II

Fund Type

Diversified Private Equity

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3.5M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Cota Capital Service Providers

1 Service Provider

Cota Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Cota Capital Team

6 Team Members

Cota Capital has 6 team members, including , .

Name

Work History

Title

Status

Ullas Naik

Globespan Capital Partners, Icon Ventures, Broadpoint Capital, and FAC Equities

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Ullas Naik

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Globespan Capital Partners, Icon Ventures, Broadpoint Capital, and FAC Equities

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.